RAPT closes Phase 2b/2a trials after FDA hold due to liver failure SAE; Q1 net loss $30.5M

RAPT Therapeutics, Inc.

Company to close and unblind Phase 2b atopic dermatitis and Phase 2a asthma trials of zelnecirnon following FDA clinical hold.
Clinical hold triggered by one patient liver failure requiring transplant; 229 patients enrolled in AD trial.
Net loss of $30.5M for Q1 2024 vs $29.3M in Q1 2023; cash and equivalents $141.6M.
Data analysis from AD trial expected Q3 2024 to inform development path and FDA discussions.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

RAPT Therapeutics, Inc. reported the quarter ended March 31, 2024 results: net income Net loss for the first quarter of 2024 was $30.5 million.

Period: the quarter ended March 31, 2024
Net income: Net loss for the first quarter of 2024 was $30.5 million
Result: reported results

Exact text from the filing

RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the first quarter ended March 31, 2024.

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0000950170-24-056297

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.